Aragen expands discovery research deal with Boehringer Ingelheim
The partnership allows for the integrated up-scaling of compounds for larger pre-clinical studies
Hyderabad: Aragen Life Sciences (formerly GVK Bio), a contract research and development organisation, headquartered in Hyderabad, expanded its discovery research agreement with Germany-based Boehringer Ingelheim, with the goal of accelerating the latter’s discovery pipeline.
This extended partnership allows Boehringer Ingelheim, a research-driven pharmaceutical company, to incorporate several design elements, synthesise, profile, and then characterise a wide range of chemotypes against key targets of interest in swift optimisation cycles.
The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties (a part of the molecule) to drive decision making with speed and accuracy is also a key component of the partnership.
Aragen will dedicate a sizable portion of its campus in Hyderabad to support this alliance, the company said.
“Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.
